* DarioHealth Corp DRIO.OQ DRIO.O is expected to show a
fall
in quarterly revenue when it reports results on May 11.
* The New York City-based company is expected to report a
16.8% decrease in revenue to $6.704 million from $8.06 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for DarioHealth Corp is
for a
loss of 50 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.
* Wall Street's median 12-month price target for DarioHealth
Corp
is $14, above its last closing price of $3.69.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.56 -0.65 -0.51 Beat 21.8
Sep. 30 2022 -0.71 -0.76 -0.64 Beat 16.1
Jun. 30 2022 -0.71 -0.71 -0.74 Missed -3.9
Mar. 31 2022 -0.96 -0.96 -0.74 Beat 22.7
Dec. -1.09 -1.06 -1.09 Missed -3.2
31 2021
Sep. 30 2021 -0.91 -0.94 -1.18 Missed -26.1
Jun. 30 2021 -0.87 -0.85 -0.99 Missed -15.8
Mar. 31 2021 -1.18 -1.04 -0.92 Beat 11.7
This summary was machine generated May 9 at 17:44 GMT. All
figures in US dollars unless otherwise stated